Inviting an author to review:
Find an author and click ‘Invite to review selected article’ near their name.
Search for authorsSearch for similar articles
2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Analysis of the genomic landscapes of Barbadian and Nigerian women with triple negative breast cancer

      research-article
      1 , 2 , 3 , 4 , 2 , 5 , 6 , 5 , 7 , 8 , 9 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 1 , 21 , 21 , 3 , 3 , 3 , 3 , 1 , 22 , 23 , 24 , 25 , 3 , 1 , 2 ,
      Cancer Causes & Control
      Springer International Publishing
      Triple negative breast cancer, Women of African ancestry, Whole exome sequencing, Genomics

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Purpose

          Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype that disproportionately affects women of African ancestry (WAA) and is often associated with poor survival. Although there is a high prevalence of TNBC across West Africa and in women of the African diaspora, there has been no comprehensive genomics study to investigate the mutational profile of ancestrally related women across the Caribbean and West Africa.

          Methods

          This multisite cross-sectional study used 31 formalin-fixed paraffin-embedded (FFPE) samples from Barbadian and Nigerian TNBC participants. High-resolution whole exome sequencing (WES) was performed on the Barbadian and Nigerian TNBC samples to identify their mutational profiles and comparisons were made to African American, European American and Asian American sequencing data obtained from The Cancer Genome Atlas (TCGA). Whole exome sequencing was conducted on tumors with an average of 382 × coverage and 4335 × coverage for pooled germline non-tumor samples.

          Results

          Variants detected at high frequency in our WAA cohorts were found in the following genes NBPF12, PLIN4, TP53 and BRCA1. In the TCGA TNBC cases, these genes had a lower mutation rate, except for TP53 (32% in our cohort; 63% in TCGA-African American; 67% in TCGA-European American; 63% in TCGA-Asian). For all altered genes, there were no differences in frequency of mutations between WAA TNBC groups including the TCGA-African American cohort. For copy number variants, high frequency alterations were observed in PIK3CA, TP53, FGFR2 and HIF1AN genes.

          Conclusion

          This study provides novel insights into the underlying genomic alterations in WAA TNBC samples and shines light on the importance of inclusion of under-represented populations in cancer genomics and biomarker studies.

          Supplementary Information

          The online version contains supplementary material available at 10.1007/s10552-022-01574-x.

          Related collections

          Most cited references64

          • Record: found
          • Abstract: found
          • Article: not found

          Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

          This article provides an update on the global cancer burden using the GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer. Worldwide, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020. Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung (11.4%), colorectal (10.0 %), prostate (7.3%), and stomach (5.6%) cancers. Lung cancer remained the leading cause of cancer death, with an estimated 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers. Overall incidence was from 2-fold to 3-fold higher in transitioned versus transitioning countries for both sexes, whereas mortality varied <2-fold for men and little for women. Death rates for female breast and cervical cancers, however, were considerably higher in transitioning versus transitioned countries (15.0 vs 12.8 per 100,000 and 12.4 vs 5.2 per 100,000, respectively). The global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020, with a larger increase in transitioning (64% to 95%) versus transitioned (32% to 56%) countries due to demographic changes, although this may be further exacerbated by increasing risk factors associated with globalization and a growing economy. Efforts to build a sustainable infrastructure for the dissemination of cancer prevention measures and provision of cancer care in transitioning countries is critical for global cancer control.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            A global reference for human genetic variation

            The 1000 Genomes Project set out to provide a comprehensive description of common human genetic variation by applying whole-genome sequencing to a diverse set of individuals from multiple populations. Here we report completion of the project, having reconstructed the genomes of 2,504 individuals from 26 populations using a combination of low-coverage whole-genome sequencing, deep exome sequencing, and dense microarray genotyping. We characterized a broad spectrum of genetic variation, in total over 88 million variants (84.7 million single nucleotide polymorphisms (SNPs), 3.6 million short insertions/deletions (indels), and 60,000 structural variants), all phased onto high-quality haplotypes. This resource includes >99% of SNP variants with a frequency of >1% for a variety of ancestries. We describe the distribution of genetic variation across the global sample, and discuss the implications for common disease studies.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Integrative Genomics Viewer

              To the Editor Rapid improvements in sequencing and array-based platforms are resulting in a flood of diverse genome-wide data, including data from exome and whole genome sequencing, epigenetic surveys, expression profiling of coding and non-coding RNAs, SNP and copy number profiling, and functional assays. Analysis of these large, diverse datasets holds the promise of a more comprehensive understanding of the genome and its relation to human disease. Experienced and knowledgeable human review is an essential component of this process, complementing computational approaches. This calls for efficient and intuitive visualization tools able to scale to very large datasets and to flexibly integrate multiple data types, including clinical data. However, the sheer volume and scope of data poses a significant challenge to the development of such tools. To address this challenge we developed the Integrative Genomics Viewer (IGV), a lightweight visualization tool that enables intuitive real-time exploration of diverse, large-scale genomic datasets on standard desktop computers. It supports flexible integration of a wide range of genomic data types including aligned sequence reads, mutations, copy number, RNAi screens, gene expression, methylation, and genomic annotations (Figure S1). The IGV makes use of efficient, multi-resolution file formats to enable real-time exploration of arbitrarily large datasets over all resolution scales, while consuming minimal resources on the client computer (see Supplementary Text). Navigation through a dataset is similar to Google Maps, allowing the user to zoom and pan seamlessly across the genome at any level of detail from whole-genome to base pair (Figure S2). Datasets can be loaded from local or remote sources, including cloud-based resources, enabling investigators to view their own genomic datasets alongside publicly available data from, for example, The Cancer Genome Atlas (TCGA) 1 , 1000 Genomes (www.1000genomes.org/), and ENCODE 2 (www.genome.gov/10005107) projects. In addition, IGV allows collaborators to load and share data locally or remotely over the Web. IGV supports concurrent visualization of diverse data types across hundreds, and up to thousands of samples, and correlation of these integrated datasets with clinical and phenotypic variables. A researcher can define arbitrary sample annotations and associate them with data tracks using a simple tab-delimited file format (see Supplementary Text). These might include, for example, sample identifier (used to link different types of data for the same patient or tissue sample), phenotype, outcome, cluster membership, or any other clinical or experimental label. Annotations are displayed as a heatmap but more importantly are used for grouping, sorting, filtering, and overlaying diverse data types to yield a comprehensive picture of the integrated dataset. This is illustrated in Figure 1, a view of copy number, expression, mutation, and clinical data from 202 glioblastoma samples from the TCGA project in a 3 kb region around the EGFR locus 1, 3 . The investigator first grouped samples by tumor subtype, then by data type (copy number and expression), and finally sorted them by median copy number over the EGFR locus. A shared sample identifier links the copy number and expression tracks, maintaining their relative sort order within the subtypes. Mutation data is overlaid on corresponding copy number and expression tracks, based on shared participant identifier annotations. Several trends in the data stand out, such as a strong correlation between copy number and expression and an overrepresentation of EGFR amplified samples in the Classical subtype. IGV’s scalable architecture makes it well suited for genome-wide exploration of next-generation sequencing (NGS) datasets, including both basic aligned read data as well as derived results, such as read coverage. NGS datasets can approach terabytes in size, so careful management of data is necessary to conserve compute resources and to prevent information overload. IGV varies the displayed level of detail according to resolution scale. At very wide views, such as the whole genome, IGV represents NGS data by a simple coverage plot. Coverage data is often useful for assessing overall quality and diagnosing technical issues in sequencing runs (Figure S3), as well as analysis of ChIP-Seq 4 and RNA-Seq 5 experiments (Figures S4 and S5). As the user zooms below the ~50 kb range, individual aligned reads become visible (Figure 2) and putative SNPs are highlighted as allele counts in the coverage plot. Alignment details for each read are available in popup windows (Figures S6 and S7). Zooming further, individual base mismatches become visible, highlighted by color and intensity according to base call and quality. At this level, the investigator may sort reads by base, quality, strand, sample and other attributes to assess the evidence of a variant. This type of visual inspection can be an efficient and powerful tool for variant call validation, eliminating many false positives and aiding in confirmation of true findings (Figures S6 and S7). Many sequencing protocols produce reads from both ends (“paired ends”) of genomic fragments of known size distribution. IGV uses this information to color-code paired ends if their insert sizes are larger than expected, fall on different chromosomes, or have unexpected pair orientations. Such pairs, when consistent across multiple reads, can be indicative of a genomic rearrangement. When coloring aberrant paired ends, each chromosome is assigned a unique color, so that intra- (same color) and inter- (different color) chromosomal events are readily distinguished (Figures 2 and S8). We note that misalignments, particularly in repeat regions, can also yield unexpected insert sizes, and can be diagnosed with the IGV (Figure S9). There are a number of stand-alone, desktop genome browsers available today 6 including Artemis 7 , EagleView 8 , MapView 9 , Tablet 10 , Savant 11 , Apollo 12 , and the Integrated Genome Browser 13 . Many of them have features that overlap with IGV, particularly for NGS sequence alignment and genome annotation viewing. The Integrated Genome Browser also supports viewing array-based data. See Supplementary Table 1 and Supplementary Text for more detail. IGV focuses on the emerging integrative nature of genomic studies, placing equal emphasis on array-based platforms, such as expression and copy-number arrays, next-generation sequencing, as well as clinical and other sample metadata. Indeed, an important and unique feature of IGV is the ability to view all these different data types together and to use the sample metadata to dynamically group, sort, and filter datasets (Figure 1 above). Another important characteristic of IGV is fast data loading and real-time pan and zoom – at all scales of genome resolution and all dataset sizes, including datasets comprising hundreds of samples. Finally, we have placed great emphasis on the ease of installation and use of IGV, with the goal of making both the viewing and sharing of their data accessible to non-informatics end users. IGV is open source software and freely available at http://www.broadinstitute.org/igv/, including full documentation on use of the software. Supplementary Material 1
                Bookmark

                Author and article information

                Contributors
                hercules@mcmaster.ca
                xiyuliu@usc.edu
                basseybi@mcmaster.ca
                desiree.skeete@cavehill.uwi.edu
                spsmithmd@gmail.com
                aodaramola@cmul.edu.ng
                aafbanjo@cmul.edu.ng
                gobeng02@gmail.com
                evitomtu@yahoo.com
                imaekanem2013@gmail.com
                josephessien@unical.edu.ng
                christopher.obiorah@uniport.edu.ng
                ojuleac@gmail.com
                micoyedim@yahoo.com
                mdayuba10th@gmail.com
                anatomyejike@gmail.com
                jevon.c.hercules@gmail.com
                ansara4@mcmaster.ca
                ian.brain@medportal.ca
                christine.maccoll@medportal.ca
                yilixu@usc.edu
                yuxinjin@usc.edu
                changsha@usc.edu
                carpten@usc.edu
                abedard@mcmaster.ca
                gpond@mcmaster.ca
                kim.blenman@yale.edu
                zmanojlo@usc.edu
                danielj@mcmaster.ca
                Journal
                Cancer Causes Control
                Cancer Causes Control
                Cancer Causes & Control
                Springer International Publishing (Cham )
                0957-5243
                1573-7225
                6 April 2022
                6 April 2022
                2022
                : 33
                : 6
                : 831-841
                Affiliations
                [1 ]GRID grid.25073.33, ISNI 0000 0004 1936 8227, Department of Biology, , McMaster University, ; Hamilton, ON Canada
                [2 ]African Caribbean Cancer Consortium, Philadelphia, PA USA
                [3 ]GRID grid.42505.36, ISNI 0000 0001 2156 6853, Department of Translational Genomics, Keck School of Medicine, , University of Southern California, ; Los Angeles, CA USA
                [4 ]GRID grid.25073.33, ISNI 0000 0004 1936 8227, Stem Cell and Cancer Research Institute (SCC-RI), , McMaster University, ; Hamilton, ON Canada
                [5 ]GRID grid.412886.1, ISNI 0000 0004 0592 769X, Faculty of Medical Sciences, , University of the West Indies at Cave Hill, ; Bridgetown, Barbados
                [6 ]GRID grid.415521.6, ISNI 0000 0004 0570 5165, Department of Pathology, , Queen Elizabeth Hospital, ; Bridgetown, Barbados
                [7 ]GRID grid.415521.6, ISNI 0000 0004 0570 5165, Department of Radiation Oncology, , Queen Elizabeth Hospital, ; Bridgetown, Barbados
                [8 ]Present Address: Cancer Specialists Inc, Bridgetown, Barbados
                [9 ]GRID grid.411283.d, ISNI 0000 0000 8668 7085, Department of Anatomic and Molecular Pathology, , Lagos University Teaching Hospital, ; Lagos, Nigeria
                [10 ]GRID grid.413097.8, ISNI 0000 0001 0291 6387, Department of Pathology, , University of Calabar Teaching Hospital, ; Calabar, Nigeria
                [11 ]GRID grid.413097.8, ISNI 0000 0001 0291 6387, Department of Obstetrics & Gynaecology, College of Medical Sciences, , University of Calabar Teaching Hospital, ; Calabar, Nigeria
                [12 ]GRID grid.413097.8, ISNI 0000 0001 0291 6387, Department of Pathology, College of Medical Sciences, , University of Calabar Teaching Hospital, ; Calabar, Nigeria
                [13 ]GRID grid.413097.8, ISNI 0000 0001 0291 6387, Division of General and Breast Surgery, , University of Calabar Teaching Hospital, ; Calabar, Nigeria
                [14 ]GRID grid.412738.b, Department of Anatomical Pathology, , University of Port Harcourt Teaching Hospital, ; Port Harcourt, Nigeria
                [15 ]GRID grid.412738.b, Department of Chemical Pathology, , University of Port Harcourt Teaching Hospital, ; Port Harcourt, Nigeria
                [16 ]GRID grid.411946.f, ISNI 0000 0004 1783 4052, Department of Surgery, , Jos University Teaching Hospital, ; Jos, Nigeria
                [17 ]GRID grid.411946.f, ISNI 0000 0004 1783 4052, Department of Pathology, , Jos University Teaching Hospital, ; Jos, Nigeria
                [18 ]Meena Histopathology and Cytology Laboratory, Jos, Nigeria
                [19 ]GRID grid.12916.3d, ISNI 0000 0001 2322 4996, Department of Mathematics, , University of the West Indies at Mona, ; Kingston, Jamaica
                [20 ]GRID grid.12955.3a, ISNI 0000 0001 2264 7233, Present Address: Wang Yanan Institute for Studies in Economics, Xiamen University, ; Xiamen, China
                [21 ]GRID grid.25073.33, ISNI 0000 0004 1936 8227, Department of Pathology and Molecular Medicine, , McMaster University, ; Hamilton, ON Canada
                [22 ]GRID grid.25073.33, ISNI 0000 0004 1936 8227, Department of Health Research Methods, Evidence, and Impact, , McMaster University, ; Hamilton, ON Canada
                [23 ]GRID grid.25073.33, ISNI 0000 0004 1936 8227, Department of Oncology, , McMaster University, ; Hamilton, ON Canada
                [24 ]GRID grid.433818.5, Department of Internal Medicine, Section of Medical Oncology, , Yale Cancer Center, School of Medicine, ; New Haven, CT USA
                [25 ]GRID grid.47100.32, ISNI 0000000419368710, Department of Computer Science, School of Engineering and Applied Science, , Yale University, ; New Haven, CT USA
                Author information
                http://orcid.org/0000-0002-3497-0772
                Article
                1574
                10.1007/s10552-022-01574-x
                9085672
                35384527
                d0e98bbc-61c1-42a9-91d7-f6aa69d97dea
                © The Author(s) 2022

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 9 September 2021
                : 12 March 2022
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100000038, Natural Sciences and Engineering Research Council of Canada;
                Award ID: RGPIN-2020-06822
                Award Recipient :
                Funded by: FundRef http://dx.doi.org/10.13039/501100000024, Canadian Institutes of Health Research;
                Award ID: PJT-173223
                Award Recipient :
                Funded by: Canadian Breast Cancer Foundation/Canadian Cancer Society Research Institute
                Award ID: 316252
                Award Recipient :
                Categories
                Original Paper
                Custom metadata
                © Springer Nature Switzerland AG 2022

                Oncology & Radiotherapy
                triple negative breast cancer,women of african ancestry,whole exome sequencing,genomics

                Comments

                Comment on this article